Chronic hepatitis C;Chronische Hepatitis C

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 50, 2010, Pages 2525-2534

  Grammatikos, G ^a   Sarrazin, C ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

clinical practice guideline; hepatitis C; viral hepatitis

Indexed keywords

CHRONIC HEPATITIS; HEPATITIS C; HUMAN; REVIEW;

ALGORITHMS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 78650111517     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1269423     Document Type: Review

References (30)

1. Alter M J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007 13 2436-2441
2. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009 16 300-14
3. Deuffic-Burban S, Deltenre P, Louvet A et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008 49 175-183
4. Foster G R., Fried M W., Hadziyannis S J. et al. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) and ribavirin. Scand J Gastroenterol 2007 42 247-255
5. Friedrich-Rust M, Ong M F., Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008 134 960-974
6. Friedrich-Rust M, Wunder K, Kriener S et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009 252 595-604
7. Ge D, Fellay J, Thompson A J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 399-401
8. Gebo K A., Chander G, Jenckes M W. et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002 36 S84-S92
9. Heathcote E J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004 127 S294-S302
10. Hézode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 360 1839-1850
11. Hnatyszyn H J. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005 10 1-11
12. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008 49 634-51
13. Kwo P Y., Lawitz E J., McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010 376 705-716
14. Manns M, Zeuzem S, Sood A et al. Reduced dose and duration of peginterferon alpha-2b and weight-based ribavirin in European and Asian genotype 2 and 3 chronic hepatitis C patients (REDD 2/3 trial). J Hepatol 2009 50 A144
15. McHutchison J G., Manns M P., Muir A J. et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010 362 1292-1303
16. Neal K R., Ramsay S, Thomson B J. et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007 56 1098-1104
17. Niederau C, Bemba G, Kautz A. Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany socioeconomic aspects in hepatitis C. Z Gastroenterol 2006 44 305-317
18. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010 59 1245-1251
19. Perz J F., Armstrong G L., Farrington L A. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 529-538
20. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 825-832
21. Poynard T, McHutchison J, Davis G L. et al. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000 32 1131-1137
22. Sarrazin C, Berg T, Ross R S. et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: German guidelines on the management of HCV infection. Z Gastroenterol 2010 48 289-351
23. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010 138 447-462
24. Schirmacher P, Fleig W E., Tannapfel A et al. Bioptische Diagnostik der chronischen Hepatitis. Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Pathologie (DGP), der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und des Kompetenznetzes Hepatitis (HepNet). Pathologe 2004 25 337-348
25. Stravitz R T., Heuman D M., Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008 121 119-126
26. Thein H H., Yi Q, Dore G J. et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008 48 418-431
27. Thierfelder W, Hellenbrand W, Meisel H et al. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001 17 429-435
28. Veldt B J., Heathcote E J., Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 147 677-684
29. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007 45 806-816 (Pubitemid 46450632)
30. Zeuzem S, Diago M, Gane E et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004 127 1724-1732